{"id":"W2753742685","doi":"10.1016/j.jid.2017.07.592","title":"397 Fifty two-week efficacy and safety results from SPIRIT-P1: A Phase 3 study of ixekizumab in patients with active psoriatic arthritis","year":2017,"lang":"en","type":"article","venue":"Journal of Investigative Dermatology","topic":"Autoimmune and Inflammatory Disorders Research","field":"Medicine","cited_by":7,"is_retracted":false,"has_abstract":false,"ca_institutions":"University of Toronto","funders":"","keywords":"Medicine; Ixekizumab; Psoriatic arthritis; Placebo; Adalimumab; Adverse effect; Internal medicine; Psoriasis; Population; Arthritis; Dermatology; Rheumatoid arthritis; Secukinumab","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001192322,0.000715074,0.001466691,0.0002818884,0.0004146968,0.0006240663,0.000466201,0.0007756707,0.003310326],"category_scores_gemma":[0.0007422118,0.000363113,0.001608119,0.0002113559,0.0005426994,0.0005145136,0.0002612899,0.00218378,0.0008363422],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004035785,"about_ca_system_score_gemma":0.0005558056,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005767486,"about_ca_topic_score_gemma":0.0009206627,"domain_scores_codex":[0.9995103,0.0001558369,0.00004637704,0.00007482587,0.00008160596,0.0001310963],"domain_scores_gemma":[0.9994825,0.000134902,0.0000966489,0.00006133848,0.0000313914,0.0001933005],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6779583,0.04768822,0.01133473,0.0009070922,0.00224524,0.0003229909,0.000353437,0.002505567,0.06737933,0.0001881366,0.002896856,0.1862202],"study_design_scores_gemma":[0.3523549,0.5856593,0.0494194,0.00004360417,0.001209403,0.0002553048,0.00009197339,0.001113306,0.007017934,0.0001813475,0.002592149,0.00006124254],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9961654,0.001151055,0.0004173205,0.000111246,0.00005711632,0.0004513288,0.0004726738,0.00008385744,0.001090074],"genre_scores_gemma":[0.9953636,0.0006103524,0.0005684327,0.0003978265,0.00007836366,0.0004188063,0.0009662378,0.00002376923,0.001572561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.003310326,"threshold_uncertainty_score":0.01107413,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02908035995489525,"score_gpt":0.3204822035978377,"score_spread":0.2914018436429425,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}